Lennox-Gastaut syndrome

What is Lennox-Gastaut syndrome?

Lennox-Gastaut syndrome (LGS) is a rare and severe form of childhood epilepsy characterized by multiple types of seizures, distinctive brain wave patterns, and developmental challenges. This complex neurological condition typically begins between ages 2-8 years and affects approximately 2 in every 100,000 children. LGS accounts for about 1-4% of all childhood epilepsies but represents one of the most challenging forms to treat. The syndrome profoundly impacts children and families, often requiring lifelong management and specialized care.

Key statistics

Symptoms

Primary symptoms: Multiple seizure types, slow spike-and-wave brain activity, intellectual disability, developmental delays, behavioral problems, frequent falls.

The hallmark of LGS is the presence of multiple seizure types that are often difficult to control. Tonic seizures cause sudden muscle stiffening, particularly during sleep, and may cause the child to fall if standing. Atonic seizures, also called “drop attacks,” involve sudden loss of muscle tone, causing the child to fall abruptly to the ground. Atypical absence seizures manifest as brief episodes of altered consciousness with subtle behavioral changes.

Many children also experience tonic-clonic seizures (generalized convulsions), myoclonic seizures (sudden muscle jerks), and focal seizures that may progress to generalized seizures. The frequency and severity of seizures vary significantly between individuals.

Submit Your Paper

Beyond seizures, most children develop intellectual disability of varying degrees, with cognitive decline often occurring after seizure onset. Behavioral problems are common, including hyperactivity, aggression, autism spectrum behaviors, and sleep disturbances. Motor difficulties may include unsteady gait, coordination problems, and delayed motor milestones.

Causes and risk factors

LGS has diverse underlying causes, with approximately 70% of cases having an identifiable structural or genetic origin. Structural causes include brain malformations, cortical dysplasia, tuberous sclerosis complex, brain infections, traumatic brain injury, and stroke. Genetic causes involve mutations in various genes including SCN1A, CDKL5, SCN2A, STXBP1, and others.

About 20-30% of LGS cases evolve from other epilepsy syndromes, particularly West syndrome (infantile spasms). In approximately 30% of cases, no underlying cause can be identified despite thorough investigation.

Risk factors include previous seizure disorders, developmental delays, family history of epilepsy, complications during pregnancy or birth, and certain genetic syndromes. Males are more frequently affected than females.

Prevention

LGS cannot be prevented in most cases, particularly when caused by genetic mutations or structural brain abnormalities. However, some preventive measures may reduce risk in certain situations. Preventing brain injuries through proper safety measures, prompt treatment of brain infections, and optimal prenatal care may reduce the risk of acquired forms of LGS.

For families with a child diagnosed with LGS, genetic counseling is recommended to assess recurrence risks and discuss family planning options. Genetic testing may identify specific mutations that inform inheritance patterns and enable more precise genetic counseling for future pregnancies.

Complications

Without proper treatment, LGS leads to frequent seizures that significantly impact development and quality of life. Status epilepticus, a prolonged seizure emergency, occurs more frequently in LGS patients. Repeated falls from drop attacks can cause serious injuries, including head trauma and fractures.

Long-term complications include progressive intellectual disability, severe behavioral problems, and increased mortality risk. The condition often leads to significant educational challenges, social isolation, and reduced independence. Many individuals require lifelong supervision and care. Sudden unexpected death in epilepsy (SUDEP) risk is elevated in LGS compared to other epilepsy types.

Diagnosis

LGS diagnosis requires specific clinical criteria: multiple seizure types (particularly tonic, atonic, and atypical absence seizures), characteristic EEG pattern showing slow spike-and-wave complexes (1.5-2.5 Hz), and intellectual disability or developmental regression.

Electroencephalogram (EEG) is essential, showing the pathognomonic slow spike-and-wave pattern during wakefulness and fast rhythms (10 Hz or faster) during sleep. Video-EEG monitoring may be necessary to capture and characterize different seizure types.

Brain MRI identifies structural abnormalities in approximately 70% of cases. Genetic testing using epilepsy gene panels or whole exome sequencing may identify underlying genetic causes. Additional metabolic testing may be considered based on clinical presentation.

Treatment

LGS treatment focuses on seizure control, developmental support, and improving quality of life. Multiple anti-seizure medications are typically required, often in combination.

FDA-approved medications for LGS include cannabidiol, rufinamide, clobazam, felbamate, and fenfluramine. Other commonly used medications include valproic acid, lamotrigine, topiramate, and levetiracetam.

Surgical options may be considered for selected patients, including corpus callosotomy (disconnecting brain hemispheres to reduce drop attacks), vagus nerve stimulation, or resective surgery if a focal lesion is identified.

Ketogenic diet and other dietary therapies can provide significant seizure reduction in some children. Physical, occupational, and speech therapy support development and function.

Prognosis

LGS generally has a challenging prognosis, with most patients experiencing lifelong seizures and intellectual disability. Complete seizure freedom is achieved in only 5-10% of patients, though seizure reduction and improved quality of life are attainable goals.

Long-term outcomes vary significantly based on underlying cause, age of onset, and response to treatment. Patients with genetic causes may have more severe outcomes than those with acquired causes. Early onset typically correlates with worse developmental outcomes.

Most individuals require lifelong supervision and assistance with daily activities. However, with optimal treatment and support, many people with LGS can participate in educational programs, develop meaningful relationships, and experience improved seizure control.

Quality of life

Living with LGS requires comprehensive support and adaptive strategies. Protective helmets may prevent injury during drop attacks. Home safety modifications reduce fall-related injuries. Maintaining consistent sleep schedules and identifying seizure triggers can help optimize seizure control.

Educational support through individualized education programs (IEPs) addresses learning needs. Behavioral interventions and mental health support benefit both patients and families. Regular exercise, within safety limitations, supports overall health and may improve seizure control.

Family support is crucial, as caregivers face significant stress and financial burden. Respite care services provide essential relief for families. Building support networks through patient organizations and support groups offers valuable resources and community connections.

Pregnancy and fertility

Fertility may be reduced in women with LGS due to seizure effects and medication impacts on hormonal function. Pregnancy planning requires careful coordination with healthcare providers to optimize seizure control while minimizing medication risks to the developing baby.

Many anti-seizure medications pose teratogenic risks, requiring medication adjustments before conception when possible. Folic acid supplementation is essential. Genetic counseling provides important information about recurrence risks, which vary depending on the underlying cause of LGS.

Children

LGS primarily affects children, with onset typically in early childhood. Early intervention services, including physical, occupational, and speech therapy, optimize developmental outcomes. Educational planning should begin early, focusing on individualized approaches that accommodate cognitive and behavioral challenges.

Transition planning becomes important as children approach adulthood, addressing continued medical care, educational services, vocational training, and guardianship considerations. Families need support navigating complex care coordination and advocating for appropriate services.

When to see a doctor

Seek immediate emergency care for seizures lasting longer than 5 minutes, difficulty breathing after a seizure, seizures occurring in clusters, or significant injuries from falls.

Schedule urgent appointments for new seizure types, increased seizure frequency, significant behavioral changes, or medication side effects. Regular follow-up with epilepsy specialists is essential for ongoing management and treatment optimization.

Parents should maintain seizure diaries and report changes in seizure patterns, development, or behavior to healthcare providers.

Regional context

LGS prevalence in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean appears consistent with global estimates, though comprehensive epidemiological data remains limited. Regional research collaborations and patient registries could provide valuable insights into local disease patterns and treatment outcomes.

Healthcare infrastructure development and specialist training in these regions continue to evolve, with opportunities for international collaboration in LGS research and care. The Global Medical Journal welcomes contributions from regional healthcare providers and researchers to enhance understanding of LGS in these populations.

Research and clinical trials

Current research focuses on novel anti-seizure medications, improved understanding of disease mechanisms, and personalized treatment approaches based on genetic findings. Gene therapy and precision medicine approaches show promise for specific genetic forms of LGS.

Recent breakthroughs include the approval of fenfluramine for seizure reduction and ongoing studies of dietary interventions and neurostimulation techniques. Clinical trials are investigating new medications, combination therapies, and innovative treatment approaches.

Patients and families can search for relevant clinical trials at ClinicalTrials.gov using terms like “Lennox-Gastaut syndrome” and their location. Participation in research studies contributes to advancing treatment options for future patients.

Frequently asked questions

Will my child outgrow Lennox-Gastaut syndrome?

LGS is typically a lifelong condition that does not resolve with age. However, seizure patterns may change over time, and some individuals experience improvement in seizure frequency with optimal treatment.

Can children with LGS attend regular school?

Educational placement depends on individual cognitive abilities and seizure control. Some children benefit from inclusive settings with support, while others require specialized educational programs tailored to their specific needs.

Is LGS hereditary?

LGS can have genetic causes, but inheritance patterns vary widely depending on the underlying genetic mutation. Genetic counseling can provide specific information about recurrence risks for individual families.

What should I do during my child’s seizure?

Keep the child safe by moving them away from hazards, cushion their head, time the seizure, and stay calm. Do not put anything in their mouth. Call emergency services if the seizure lasts longer than 5 minutes.

Are there any dietary restrictions for children with LGS?

While there are no universal dietary restrictions, some children benefit from specialized diets like the ketogenic diet. Medication interactions with food should be discussed with healthcare providers, and maintaining regular meal times can help optimize medication absorption.

Support and resources

• LGS Foundation: www.lgsfoundation.org – Comprehensive resources, research funding, and family support
• Epilepsy Foundation: www.epilepsy.com – Educational resources and advocacy
• NORD (National Organization for Rare Disorders): rarediseases.org – Rare disease information and support
• Orphanet: www.orpha.net – International rare disease database
• EURORDIS: www.eurordis.org – European rare disease advocacy
• International League Against Epilepsy: www.ilae.org – Professional organization with patient resources

Related conditions

• West syndrome – Often precedes LGS
• Dravet syndrome – Another severe childhood epilepsy
• Tuberous sclerosis complex – Genetic condition that can cause LGS
• Doose syndrome – Childhood epilepsy with myoclonic seizures
• CDKL5 deficiency disorder – Genetic cause of early-onset epilepsy

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.